Ligand Pharma (LGDN) Financial Statements

0 Followers

Ligand Pharma Financial Overview

Ligand Pharma's market cap is currently CHF5.30B. The company's EPS TTM is CHF2.59; its P/E ratio is 124.61; Ligand Pharma is scheduled to report earnings on October 29, 2026, and the estimated EPS forecast is CHF2.36. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 268.09M	$ 167.13M	$ 131.31M	$ 196.25M	$ 241.54M
Gross Profit	$ 261.50M	$ 156.06M	$ 96.27M	$ 143.42M	$ 179.37M
Operating Income	$ 47.20M	$ -22.61M	$ 11.94M	$ 3.04M	$ 103.85M
EBITDA	$ 192.74M	$ 40.79M	$ 100.84M	$ 81.20M	$ 142.77M
Net Income	$ 124.45M	$ -4.03M	$ 52.15M	$ -33.36M	$ 57.14M
Balance Sheet
Cash & Short-Term Investments	$ 733.52M	$ 256.17M	$ 170.31M	$ 211.87M	$ 341.11M
Total Assets	$ 1.56B	$ 941.77M	$ 787.22M	$ 762.67M	$ 1.30B
Total Debt	$ 451.49M	$ 7.11M	$ 6.17M	$ 87.75M	$ 324.39M
Net Debt	$ 276.56M	$ -65.20M	$ -16.79M	$ 42.74M	$ 304.86M
Total Liabilities	$ 543.42M	$ 111.33M	$ 86.30M	$ 165.18M	$ 476.43M
Stockholders' Equity	$ 1.02B	$ 830.44M	$ 700.91M	$ 597.49M	$ 821.16M
Cash Flow
Free Cash Flow	$ 48.91M	$ 77.41M	$ -4.27M	$ 119.93M	$ 70.04M
Operating Cash Flow	$ 49.36M	$ 97.05M	$ 49.58M	$ 137.85M	$ 78.80M
Investing Cash Flow	$ -377.32M	$ -143.66M	$ -11.68M	$ 163.62M	$ 30.52M
Financing Cash Flow	$ 428.22M	$ 97.14M	$ -59.95M	$ -275.99M	$ -137.76M

Currency in USD

Ligand Pharma Earnings and Revenue History

Income Statement >

Ligand Pharma Debt to Assets

Balance Sheet >

Ligand Pharma Cash Flow

Cash Flow >

Ligand Pharma Forecast EPS vs Actual EPS

Earnings >